Cao Renhai, Eriksson Anna, Kubo Hajime, Alitalo Kari, Cao Yihai, Thyberg Johan
Microbiology and Tumor Biology Center, Karolinska Institutet, Stockholm, Sweden.
Circ Res. 2004 Mar 19;94(5):664-70. doi: 10.1161/01.RES.0000118600.91698.BB. Epub 2004 Jan 22.
Several endothelial growth factors induce both blood and lymphatic angiogenesis. However, a systematic comparative study of the impact of these factors on vascular morphology and function has been lacking. In this study, we report a quantitative analysis of the structure and macromolecular permeability of FGF-2-, VEGF-A-, and VEGF-C-induced blood and lymphatic vessels. Our results show that VEGF-A stimulated formation of disorganized, nascent vasculatures as a result of fusion of blood capillaries into premature plexuses with only a few lymphatic vessels. Ultrastructural analysis revealed that VEGF-A-induced blood vessels contained high numbers of endothelial fenestrations that mediated high permeability to ferritin, whereas the FGF-2-induced blood vessels lacked vascular fenestrations and showed only little leakage of ferritin. VEGF-C induced approximately equal amounts of blood and lymphatic capillaries with endothelial fenestrations present only on blood capillaries, mediating a medium level of ferritin leakage into the perivascular space. No endothelial fenestrations were found in FGF-2-, VEGF-A-, or VEGF-C-induced lymphatic vessels. These findings highlight the structural and functional differences between blood and lymphatic vessels induced by FGF-2, VEGF-A, and VEGF-C. Such information is important to consider in development of novel therapeutic strategies using these angiogenic factors.
几种内皮生长因子可同时诱导血管生成和淋巴管生成。然而,目前缺乏对这些因子对血管形态和功能影响的系统比较研究。在本研究中,我们报告了对FGF-2、VEGF-A和VEGF-C诱导的血管和淋巴管的结构及大分子通透性的定量分析。我们的结果表明,VEGF-A刺激形成无序的新生脉管系统,这是由于毛细血管融合成仅含少量淋巴管的早熟丛状结构所致。超微结构分析显示,VEGF-A诱导的血管含有大量内皮窗孔,可介导对铁蛋白的高通透性,而FGF-2诱导的血管缺乏血管窗孔,仅显示少量铁蛋白渗漏。VEGF-C诱导的血管和淋巴管数量大致相等,内皮窗孔仅存在于血管中,介导中等水平的铁蛋白渗漏到血管周围间隙。在FGF-2、VEGF-A或VEGF-C诱导的淋巴管中未发现内皮窗孔。这些发现突出了FGF-2、VEGF-A和VEGF-C诱导的血管和淋巴管之间的结构和功能差异。在开发使用这些血管生成因子的新型治疗策略时,考虑这些信息很重要。